Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma
Metaplastic breast carcinoma (MBC) is a heterogeneous group of infrequent triple negative (TN) invasive carcinomas with poor prognosis. MBCs have a different clinical behavior from other types of triple negative breast cancer (TNBC), being more resistant to standard chemotherapy. MBCs are an example...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-07-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/14/7398 |
| _version_ | 1797526971810316288 |
|---|---|
| author | Silvia González-Martínez Belén Pérez-Mies David Pizarro Tamara Caniego-Casas Javier Cortés José Palacios |
| author_facet | Silvia González-Martínez Belén Pérez-Mies David Pizarro Tamara Caniego-Casas Javier Cortés José Palacios |
| author_sort | Silvia González-Martínez |
| collection | DOAJ |
| description | Metaplastic breast carcinoma (MBC) is a heterogeneous group of infrequent triple negative (TN) invasive carcinomas with poor prognosis. MBCs have a different clinical behavior from other types of triple negative breast cancer (TNBC), being more resistant to standard chemotherapy. MBCs are an example of tumors with activation of epithelial–mesenchymal transition (EMT). The mechanisms involved in EMT could be responsible for the increase in the infiltrative and metastatic capacity of MBCs and resistance to treatments. In addition, a relationship between EMT and the immune response has been seen in these tumors. In this sense, MBC differ from other TN tumors showing a lower number of tumor-infiltrating lymphocytes (TILS) and a higher percentage of tumor cells expressing programmed death-ligand 1 (PD-L1). A better understanding of the relationship between the immune system and EMT could provide new therapeutic approaches in MBC. |
| first_indexed | 2024-03-10T09:36:55Z |
| format | Article |
| id | doaj.art-0b50e28cacdb4a9bbed152c6a089a341 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T09:36:55Z |
| publishDate | 2021-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-0b50e28cacdb4a9bbed152c6a089a3412023-11-22T03:57:54ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-07-012214739810.3390/ijms22147398Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast CarcinomaSilvia González-Martínez0Belén Pérez-Mies1David Pizarro2Tamara Caniego-Casas3Javier Cortés4José Palacios5Clinical Researcher, Hospital Ramón y Cajal, 28034 Madrid, SpainDepartment of Pathology, Hospital Ramón y Cajal, 28034 Madrid, SpainInstitute Ramón y Cajal for Health Research (IRYCIS), 28034 Madrid, SpainInstitute Ramón y Cajal for Health Research (IRYCIS), 28034 Madrid, SpainCIBER-ONC, Instituto de Salud Carlos III, 28029 Madrid, SpainDepartment of Pathology, Hospital Ramón y Cajal, 28034 Madrid, SpainMetaplastic breast carcinoma (MBC) is a heterogeneous group of infrequent triple negative (TN) invasive carcinomas with poor prognosis. MBCs have a different clinical behavior from other types of triple negative breast cancer (TNBC), being more resistant to standard chemotherapy. MBCs are an example of tumors with activation of epithelial–mesenchymal transition (EMT). The mechanisms involved in EMT could be responsible for the increase in the infiltrative and metastatic capacity of MBCs and resistance to treatments. In addition, a relationship between EMT and the immune response has been seen in these tumors. In this sense, MBC differ from other TN tumors showing a lower number of tumor-infiltrating lymphocytes (TILS) and a higher percentage of tumor cells expressing programmed death-ligand 1 (PD-L1). A better understanding of the relationship between the immune system and EMT could provide new therapeutic approaches in MBC.https://www.mdpi.com/1422-0067/22/14/7398MBCmetaplastic breast carcinomaEMTepithelial-mesenchymal transition immune system |
| spellingShingle | Silvia González-Martínez Belén Pérez-Mies David Pizarro Tamara Caniego-Casas Javier Cortés José Palacios Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma International Journal of Molecular Sciences MBC metaplastic breast carcinoma EMT epithelial-mesenchymal transition immune system |
| title | Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma |
| title_full | Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma |
| title_fullStr | Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma |
| title_full_unstemmed | Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma |
| title_short | Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma |
| title_sort | epithelial mesenchymal transition and immune response in metaplastic breast carcinoma |
| topic | MBC metaplastic breast carcinoma EMT epithelial-mesenchymal transition immune system |
| url | https://www.mdpi.com/1422-0067/22/14/7398 |
| work_keys_str_mv | AT silviagonzalezmartinez epithelialmesenchymaltransitionandimmuneresponseinmetaplasticbreastcarcinoma AT belenperezmies epithelialmesenchymaltransitionandimmuneresponseinmetaplasticbreastcarcinoma AT davidpizarro epithelialmesenchymaltransitionandimmuneresponseinmetaplasticbreastcarcinoma AT tamaracaniegocasas epithelialmesenchymaltransitionandimmuneresponseinmetaplasticbreastcarcinoma AT javiercortes epithelialmesenchymaltransitionandimmuneresponseinmetaplasticbreastcarcinoma AT josepalacios epithelialmesenchymaltransitionandimmuneresponseinmetaplasticbreastcarcinoma |